CD274 and hepatocellular carcinoma: However, the distinct immunosuppressive tumor microenvironment of MASLD/MASH-associated HCC, characterized by reduced PD-L1 expression and T-cell receptor diversity, presents unique challenges to the efficacy of immunotherapy [23,24,25].